You mean like a 10-k or 10-q that are missing and overdue? Or maybe an update on the OSA program and new formulations, presumably in preclinicals?
Or a shareholder update as to approach with NIH, potential milestones and paths forward? Does seem rather odd, all things considered.....
While certainly there is a ton of risk as these OTC equities deal with a ton of ridiculous issues that can be hugely negative for investors.... I optimistically look at a few of the key happenings past 6 months and piece together what "could be". They hired a VP last December who basically sounds like a closer/deal maker and has equity incentive to push across the goal line. Then the continued success stories and publications concerning KRM-II-81 progressing positively with many possible paths to develop for multiple medical indications that need better treatment options. The last real communication was the CEO interview in March. In a nutshell, that interview seemed genuinely confident in completing the NIH preclinicals while hoping to open investment "pursestrings". My guess is this is where they are at. Awaiting to see if the NIH trials prove their candidate drug to be "somewhat" valuable, "extremely" valuable or not that valuable at all. This determination probably sets the course for all other future endeavors.
Someone is correct in suggesting it is all a gamble. Pharma business is a gamble. All OTC investing is a gamble. Prepare to lose and hope to be enormously successful. For me the risk v. reward ratio continues to be tremendous for speculative money. Good Luck to all...
